Xencor (XNCR) Change in Acquisitions & Divestments (2015 - 2026)
Xencor (XNCR) posted quarterly Change in Acquisitions & Divestments of $100.0 million for Q1 2026, down 15.98% year-over-year from $119.0 million in Q1 2025, and up 14.9% quarter-over-quarter from $87.0 million in Q4 2025.
Analysis
Xencor (XNCR) Change in Acquisitions & Divestments (2015 - 2026) Analysis & Trends
Xencor (XNCR) has reported Change in Acquisitions & Divestments for 12 consecutive years, with $100.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments fell 15.98% year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $386.1 million (down 44.77% YoY), while the FY2025 annual figure was $405.1 million, down 31.35% from the prior year.
- Change in Acquisitions & Divestments advanced to $100.0 million in Q1 2026 per XNCR's latest filing, from $87.0 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $471.7 million in Q3 2024 and bottomed at -$339.6 million in Q3 2023.
- Historically, Change in Acquisitions & Divestments has averaged $73.0 million across 5 years, with a median of $87.0 million in 2025.
- On a YoY basis, Change in Acquisitions & Divestments climbed as much as 1093.55% in 2025 and fell as far as 1741.72% in 2025.
- Xencor's Change in Acquisitions & Divestments stood at -$205.3 million in 2022, then plunged by 65.41% to -$339.6 million in 2023, then jumped by 133.61% to $114.1 million in 2024, then slipped by 23.78% to $87.0 million in 2025, then gained by 14.9% to $100.0 million in 2026.
- Business Quant data shows XNCR's Change in Acquisitions & Divestments at $100.0 million in Q1 2026, $87.0 million in Q4 2025, and $304.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55.00 Mn |
| Mar 31, 2026 | 99.97 Mn |
| Dec 31, 2025 | 87.00 Mn |
| Sep 30, 2025 | 98.71 Mn |
| Jun 30, 2025 | 100.40 Mn |
| Mar 31, 2025 | 118.99 Mn |
| Dec 31, 2024 | 114.14 Mn |
| Sep 30, 2024 | 117.98 Mn |
| Jun 30, 2024 | 197.99 Mn |
| Mar 31, 2024 | 159.94 Mn |
| Dec 31, 2023 | 137.00 Mn |
| Sep 30, 2023 | 216.51 Mn |
| Jun 30, 2023 | 185.02 Mn |
| Mar 31, 2023 | 154.56 Mn |
| Dec 31, 2022 | 101.32 Mn |
| Sep 30, 2022 | 128.90 Mn |
| Jun 30, 2022 | 56.39 Mn |
| Mar 31, 2022 | 20.00 Mn |
| Dec 31, 2021 | 141.27 Mn |
| Sep 30, 2021 | 122.13 Mn |